Sonoma Pharmaceuticals

SNOA

Market cap $1.99M

BOULDER, CO / ACCESS Newswire / April 24, 2026 / Sonoma Pharmaceuticals, Inc. (the "Company" or "Sonoma Pharmaceuticals") (NASDAQ:SNOA), a global healthcare leader in hypochlorous acid (HOCl) technology, today announced the pricing of its public offering made on a firm commitment basis with gross proceeds to the Company expected to be approximately $4.0 million, before deducting fees and other expenses payable by the Company. The offering consists of 2,962,963 shares of common stock and 2,962,963 warrants.

BOULDER, CO / ACCESS Newswire / March 24, 2026 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader in hypochlorous acid (HOCl) technology, today announced the U.S. retail launch of its advanced HOCl-based burn relief hydrogel in CVS and Walmart stores nationwide. The hydrogel is indicated for the management of minor burns and skin irritations.

BOULDER, CO / ACCESS Newswire / March 18, 2026 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye care, dermatological conditions, podiatry, and animal health care, today announced the launch of Aquanil® AD, a hypochlorous acid based dermatology product line for sensitive skin, developed exclusively for Persōn & Covey, Inc. for distribution through its established over-the-counter dermatology channels in the United States. The Aquanil AD product line includes Aquanil AD Repair Mist, a soothing spray for irritated or damaged skin; Aquanil AD Recovery Gel, designed to help reduce the appearance of scars; and Aquanil AD Rescue Serum for relief from rashes, itching and irritation.

Revenue increased 22% for the quarter ended December 31, 2025 and 33% for the nine months ended December 31, 2025 compared to prior year Net loss and net loss per share decreased from prior year for both the three months and nine months ended December 31, 2025 EBITDAS loss decreased by $0.4 million and $0.9 million for the three and nine months ended December 31, 2025 compared to prior year BOULDER, COLORADO / ACCESS Newswire / February 10, 2026 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA),a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants, today announced financial results for its third fiscal quarter and nine months ended December 31, 2025. "Sonoma is pleased to report another quarter of revenue growth, demonstrating continued execution of our strategic priorities," remarked Amy Trombly, CEO of Sonoma Pharmaceuticals.

BOULDER, CO / ACCESS Newswire / January 28, 2026 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye care, dermatological conditions, podiatry, and animal health care, today announced the appointment of Vanessa Jacoby, Chief Business and Financial Officer of Quanta Therapeutics, Inc., to its Board of Directors and to serve as Chair of its Audit Committee. Sonoma also announced the retirement of its longtime director, Dr. Jay Birnbaum.

BOULDER, CO / ACCESS Newswire / November 13, 2025 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye care, dermatological conditions, podiatry, and animal health care, today announced that Reliefacyn® Advanced Itch-Burn-Rash-Pain Relief Hydrogel has earned the National Rosacea Society (NRS) Seal of Acceptance. The NRS introduced the Seal of Acceptance program to identify gentle skin care and cosmetic products that have been clinically tested, expertly evaluated and found to be unlikely to irritate sensitive rosacea skin - providing valuable guidance to those searching for skin care and cosmetics that may be suitable for people with rosacea.

BOULDER, CO / ACCESS Newswire / November 6, 2025 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology-based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye, oral and nasal care, dermatological conditions, podiatry, and animal health care, today announced that it will be exhibiting at MEDICA 2025 in Düsseldorf, Germany, November 17-20, 2025. MEDICA is one of the largest and most prestigious medical B2B trade fairs in the world, expected to attract 80,000 visitors from 72 countries and over 5,000 exhibitors, showcasing the latest innovations in medical technology, diagnostics, and healthcare consumables.

Revenues increased 57% for the quarter and 38% for the six months ended September 30, 2025 compared to same periods last year U.S. revenue increased 115% for the quarter and 86% for the six months ended September 30, 2025 compared to same periods last year Net loss per share decreased 46% for the quarter and 42% for the six months ended September 30, 2025 compared to same periods last year BOULDER, CO / ACCESS Newswire / November 4, 2025 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye, oral and nasal care, dermatological conditions, podiatry, and animal health care, today announced financial results for its second fiscal quarter ended September 30, 2025. "We are thrilled to report the highest quarterly revenues in Sonoma's history - $5.6 million for the three months ended September 30, 2025," said Amy Trombly, CEO of Sonoma Pharmaceuticals.

BOULDER, CO / ACCESS Newswire / October 14, 2025 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader in developing and producing stabilized hypochlorous acid (HOCl) products based on its patented Microcyn® technology, today announced the launch of a new HOCl wound cleanser manufactured by Sonoma for Medline Industries, LP. The product will be distributed by Medline into hospital systems, home healthcare and other healthcare channels across the United States.

BOULDER, COLORADO / ACCESS Newswire / October 7, 2025 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology-based stabilized hypochlorous acid (HOCl) products, today announced that it has successfully registered its manufacturing facility and listed its Microcyn-based facial spray under the FDA's Modernization of Cosmetics Regulation Act of 2022 (MoCRA). The MoCRA registration expands Sonoma's regulatory footprint, enabling the Company to manufacture and commercialize Microcyn technology products as cosmetics in the United States.